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Abstract 36 
 37 
Background: Inflammatory bowel disease (IBD) is associated with neuroendocrine cell 38 
hyperplasia. Aims: We investigated neuroendocrine cells in J-pouches of patients with ulcerative 39 
colitis undergoing restorative proctocolectomy and ileal pouch-anal anastomosis. Methods: 40 
Sections from pouch biopsies of 17 patients and ileal biopsies of 17 active IBD patients and 16 41 
controls were processed by immunohistochemistry for chromogranin A (CgA) and serotonin. 42 
Mucosal tryptophan hydroxylase (TpH)-1 and serotonin-selective reuptake transporter (SERT) 43 
transcripts were measured by quantitative RT-PCR. TpH-1 and SERT transcripts were detected 44 
in pouch biopsies cultured with infliximab or its isotype control, while IL-6 and IL-8 were 45 
measured in biopsy supernatants. Results: A significant increase in CgA-positive cells and 46 
serotonin-positive cells was observed in both pouch and IBD ileum compared to control ileum. 47 
Significantly raised transcripts of TpH-1, but not SERT, were found in IBD ileum in comparison 48 
to control ileum, with no significant difference between pouch and IBD ileum. Infliximab had no 49 
influence on ex vivo pouch expression of TpH-1 and SERT, nor on the production of IL-6 and IL-50 
8. Conclusion: We here demonstrated neuroendocrine cell hyperplasia in pouch mucosa. 51 
Further studies are needed to clarify the pathophysiological implication of this finding. 52 
 3 
 
Introduction 53 
 54 
Abnormal amount and functioning of neuroendocrine cells, which comprise at least 14 cytotypes 55 
and express the pan-neuroendocrine marker chromogranin A (CgA), have been reported in 56 
several animal models of colitis1,2 and immune-mediated intestinal disorders, including Crohn’s 57 
disease (CD),3-5 ulcerative colitis (UC)5-11 and celiac disease.12 However, how neuroendocrine 58 
cells modulate the inflammatory response in the aforementioned disorders is largely unknown. 59 
The dominant cytotype among the CgA-positive neuroendocrine cells populating the bowel 60 
mucosa is represented by serotonin-producing enterochromaffin (EC) cells.13 There is evidence 61 
that serotonin induces T-cell proliferation14 and dendritic cell activation,15 sustains immune-cell 62 
recruitment,16 and up-regulates pro-inflammatory cytokine production.17 In active celiac 63 
duodenal mucosa, EC cells are increased and serotonin stimulates interferon-g production by 64 
treated celiac biopsies grown ex vivo.12  65 
 66 
A number of studies have been published investigating neuroendocrine cells in the pouch 67 
mucosa of UC patients undergoing restorative proctocolectomy and ileal pouch-anal 68 
anastomosis (Table 1). In particular, neurotensin-, polypeptide YY- and enteroglucagon-positive 69 
cells were found to be reduced in pouch biopsies,18,19 while serotonin was over-expressed in the 70 
pouch mucosa of patients with irritable pouch syndrome.20 In contrast, no difference was 71 
observed by Pietroletti et al.19 in the mucosal expression of serotonin in pouchitis. 72 
 73 
Based on these premises, we aimed to investigate neuroendocrine cells in the pouch mucosa 74 
of patients with ulcerative colitis who underwent restorative proctocolectomy, and to assess 75 
mucosal tryptophan hydroxylase (TpH)-1, which is an enzyme involved in serotonin synthesis, 76 
and serotonin-selective reuptake transporter (SERT) transcripts both in vivo and following down-77 
regulation of inflammation obtained through tumor necrosis factor (TNF)-α blockade by 78 
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infliximab in ex vivo cultured pouch biopsies.   79 
 80 
Methods 81 
 82 
Patients and tissues. Endoscopic biopsy specimens were collected from J-pouches 83 
performed in 17 UC patients undergoing restorative proctocolectomy and ileal pouch-anal 84 
anastomosis (mean age 46.1 years, range 26-64). At biopsy collection, J-pouches had been 85 
followed-up for at least two years. None of the patients with pouch had extra-intestinal 86 
manifestations or relevant co-morbidities. In particular, coeliac disease was ruled out in all 87 
patients (negative anti-human tissue transglutaminase IgA and normal serum IgA). All patients 88 
with pouch had been treated with courses of probiotics during the year before the study, and 89 
none was being treated with antibiotics at the time of biopsy collection. Clinical, endoscopic and 90 
pathological features of patients with pouch are reported in Table 2.21 The severity of pouch 91 
histological inflammation was assessed using Moskowitz criteria,22 including both acute 92 
(neutrophilic infiltration and ulcerations) and chronic (lymphoplasmacellular infiltration in the 93 
lamina propria and colonic metaplasia) changes. No case of irritable pouch syndrome was 94 
included. Ileal biopsy samples were obtained from 17 active IBD patients (mean age 39.7 years, 95 
range 19-65). Amongst these patients, eight were affected by CD with ileal involvement and nine 96 
by UC with backwash ileitis. The mean grade of their histological inflammation was 4.6 (range 97 
3-8) in CD and 1.1 (range 1-2) in UC according to the scoring system developed by Naini and 98 
Cortina.23 Two CD patients and one UC patient suffered from concomitant spondyloarthritis. 99 
Other co-morbidities included benign essential hypertension in two CD patients, autoimmune 100 
hemolytic anaemia in one UC patient and non-alcoholic fatty liver disease in two UC patients. 101 
As regards smoking habit, one CD patient and one UC patient were current smokers. Amongst 102 
the eight CD patients, three were treated with mesalazine, one with steroids, two with antibiotics, 103 
four with thiopurines and one with methotrexate. Amongst the nine UC patients with backwash 104 
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ileitis, nine were treated with mesalazine, four with steroids and two with thiopurines. Diagnosis 105 
of CD and UC was made according to clinical and histological criteria, and the site and extent of 106 
the disease were endoscopically confirmed. Mucosal samples were also collected 107 
endoscopically from normal ileum of 16 asymptomatic patients undergoing colonoscopy for 108 
colorectal cancer screening (mean age 52.2 years, range 36–68) as controls. Informed consent 109 
was obtained in all cases and the study was performed according to the Helsinki Declaration. 110 
Some tissue samples were immediately fixed in 10% neutral buffered formalin and embedded 111 
in paraffin within 24h. Consecutive 4 µm-thick sections were cut from the selected blocks, 112 
mounted on electrostatic slides (Super Frost Plus, Menzel-Glaser, Germany) and dried 113 
overnight. After dewaxing and rehydration, sections were processed for routine histology and 114 
immunohistochemistry. Some other biopsies were used for quantitative RT-PCR or organ culture 115 
experiments. The study was authorized by the Ethical Committee of the “Luigi Sacco” University 116 
Hospital, Milan, Italy (protocol number 0002846). 117 
 118 
Intraepithelial lymphocyte (IEL) counting. Histological evaluation of hematoxylin and 119 
eosin-stained sections of pouch biopsies was undertaken by two independent observers (AV 120 
and EB) who were blinded to all clinical information. In each specimen, IEL number was counted 121 
per 100 epithelial cells. For each case, five different counts were carried out and the mean 122 
number of IELs per 100 epithelial cells was recorded. 123 
 124 
Immunohistochemistry. Serial sections were taken from paraffin blocks of pouch and ileal 125 
biopsies and stained with hematoxylin-eosin or with immunoperoxidase using anti-CgA antibody 126 
(1:9000 dilution; Dako Cytomation, Glostrup, Denmark) and anti-serotonin antibody (1:1000 127 
dilution; Monosan, Uden, The Netherlands). Neuroendocrine cell assessment was performed by 128 
counting the number of CgA-positive and serotonin-positive cells per 100 epithelial cells in well-129 
oriented crypts. For each case, five different counts were carried out and the mean number of 130 
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CgA-positive and serotonin-positive cells per 100 crypt cells was finally recorded. 131 
 132 
 133 
RNA extraction and analysis of mRNA expression by quantitative RT-PCR. Total RNA was 134 
extracted with the RNeasy mini-kit (Qiagen Sciences, Valencia, CA) according to the 135 
manufacturer’s instructions. cDNA was synthesized using 200-400 ng total RNA and the 136 
Transcriptor High Fidelity cDNA Synthesis Kit (Roche Diagnostics, Mannheim, Germany) in a 137 
final volume of 20 µL. Amplifications were performed on a LightCycler 2.0 instrument (Roche 138 
Diagnostics) using the LightCycler TaqMan Master kit (Roche Diagnostics) and validated 139 
fluorogenic TaqMan Gene Expression Assays-on-Demand for TpH-1 (Hs00188220_m1) and 140 
SERT (Hs00169010_m1), both from Applied Biosystems (Foster City, CA). Expression levels 141 
were calculated with the DDCT method following normalization to the GAPDH housekeeping 142 
gene (Universal ProbeLibrary Human GAPDH Gene Assay, Roche Diagnostics). 143 
 144 
Organ culture. Biopsies from patients with a pouch were placed in 24-well tissue culture 145 
plates (BD Biosciences, Oxford, UK; one biopsy per well) in 300 µl serum-free HL-1 medium 146 
(Cambrex Bio Science, Walkersville, MD), supplemented with 100 U/ml penicillin and 100 g/ml 147 
streptomycin (Life Technologies Ltd, Paisley, UK), and cultured at 37°C, 5%CO2 with the anti-148 
TNF-α monoclonal antibody infliximab (Remicade; Merck, Milan, Italy) or its isotype-matched 149 
control (human IgG1; Sigma-Aldrich, Poole, UK). All antibodies were used at a concentration of 150 
10 µg/ml. After 24h ex vivo culture, biopsies were collected in RNAlater until used for quantitative 151 
RT-PCR and supernatants were stored at -70°C prior to ELISA. 152 
 153 
ELISA. Interleukin (IL)-6 and chemokine IL-8 levels were measured in organ culture 154 
supernatants using the specific ELISA kit (R&D Systems, Abingdon, UK), according to the 155 
manufacturer’s instructions. 156 
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 157 
Statistical analysis. All analyses were performed using Stata 14.2 (StataCorp, College 158 
Station, TX, USA). A 2-sided p-value<0.05 was considered statistically significant. The 159 
Bonferroni correction was used for post-hoc comparisons of pouch, UC, CD and control and the 160 
significance was set at 0.017 (2-sided). Continuous variables were described as median and 161 
25th-75th percentiles. They were compared between groups (pouch/UC/CD/controls) with the 162 
Kruskal Wallis test. The Wilcoxon signed-rank test was used for paired comparisons of 163 
biomarkers levels within patients. Correlation between biomarkers were assessed with the 164 
Spearman R, together with its 95% confidence interval (95%CI).  165 
 166 
Results 167 
 168 
Immunohistochemical detection of CgA and serotonin. Numerous CgA-positive cells were 169 
evident in the crypt epithelium of patients with pouch (Figure 1A), UC (Figure 1B) and CD ileum 170 
(Figure 1C). On the other hand, CgA-positivity was found in fewer cells localized in the crypts of 171 
control ileum (Figure 1D). As shown in Figure 2A, the number of CgA-positive cells per 100 crypt 172 
cells was significantly (p<0.001) higher in the pouch mucosa (median 13.0%, 25th-75th 11.0-15.7) 173 
in comparison to control ileum (median 6.6%, 25th-75th 5.1-8.8). No significant difference was 174 
found between pouch mucosa and both UC (median 9.7%, 25th-75th 9.0-10.3) and CD ileum 175 
(median 9.1%, 25th-75th 7.9-12.8) (after Bonferroni correction), without a significant difference 176 
between UC and CD ileum. However, pooling together UC and CD, CgA-positive cells were 177 
significantly (p=0.005) increased in IBD ileum (median 9.7%, 25th-75th 8.0-11.0) in comparison 178 
to control ileum, without a significant difference between IBD ileum and pouch (data not shown). 179 
No significant difference was found between pouch mucosa of the four patients undergoing 180 
restorative proctocolectomy due to dysplasia or cancer (median 11.6%, 25th-75th 8.5-16.1) and 181 
that of the 13 patients undergoing proctocolectomy for non-neoplastic causes (median 14.5%, 182 
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25th-75th  10.5-15.7). No significant correlation was found between the percentage of CgA-183 
positive cells and the degree of acute (rs=-0.0634; p=0.8088), chronic (rs=-0.3211; p=0.2088) or 184 
acute plus chronic inflammation (rs=-0.2913; p=0.2567) in pouch mucosa (data not shown).22 185 
We also correlated the percentage of CgA-positive cells with the proportion of IELs infiltrating 186 
the pouch mucosa whose median number was 5.4% (range 2.2-11.4); however, no significant 187 
correlation (rs=-0.1075; p=0.6813) was observed between these two parameters (data not 188 
shown). 189 
 190 
Numerous serotonin-positive cells were evident in the crypt epithelium of patients with pouch 191 
(Figure 1E), UC (Figure 1F) and CD ileum (Figure 1G). On the other hand, serotonin-positivity 192 
was found in fewer cells localized in the villous and crypts compartments of control ileum (Figure 193 
1H). As shown in Figure 2B, the number of serotonin-positive cells per 100 crypt cells was 194 
significantly higher in the pouch mucosa (median 7.2%, 25th-75th 5.5-10.0, p<0.001), UC 195 
(median 8.2%, 25th-75th 7.2-8.6, p=0.006) and CD ileum (median 7.0%, 25th-75th 5.6-11.2, 196 
p=0.004) in comparison to control ileum (median 4.4%, 25th-75th 3.4-6.2), without a significant 197 
difference between pouch mucosa and both UC and CD ileum (after Bonferroni correction). No 198 
significant difference was found between UC and CD ileum (after Bonferroni correction). In 199 
addition, pooling together UC and CD, serotonin-positive cells were significantly (p<0.001) 200 
increased in IBD ileum (median 7.6%, 25th-75th 6.5-8.6) in comparison to control ileum, without 201 
a significant difference between IBD ileum and pouch (data not shown). No significant difference 202 
was found between pouch mucosa of the four patients undergoing restorative proctocolectomy 203 
due to dysplasia or cancer (median 6.5%, 25th-75th 5.6-8.7) and that of the 13 patients 204 
undergoing proctocolectomy for non-neoplastic causes (median 7.8%, 25th-75th  5.2-10.1). We 205 
found a significant, though weak, (rs=-0.4860; p=0.0479) negative correlation between the 206 
percentage of serotonin-positive cells and the degree of acute plus chronic inflammation in 207 
pouch mucosa (data not shown). Instead, no significant correlation was found between the 208 
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percentage of serotonin-positive cells and the degree of acute (rs=-0.47; p=0.0568) or chronic 209 
inflammation scores (rs=-0.4219; p=0.0916) in pouch mucosa (data not shown). We also 210 
correlated the percentage of serotonin-positive cells with the proportion of IELs infiltrating the 211 
pouch mucosa, but we did not observe any significant correlation (rs=0.2299; p=0.3748) between 212 
these two parameters (data not shown). Finally, a significant, though moderate, positive 213 
correlation (rs=0.6233; p<0.0001) was observed in all patients and control subjects between the 214 
percentage of CgA-positive cells and serotonin-positive cells (Figure 2C).  215 
 216 
Mucosal TpH-1 and SERT transcripts. Using quantitative RT-PCR, we measured the 217 
transcript levels of TpH-1 and SERT in the pouch mucosa of six patients undergoing restorative 218 
proctocolectomy, and in the ileal mucosa of six active IBD patients and ten control subjects. As 219 
shown in Figure 3A, TpH-1 transcript levels were significantly (p<0.001) higher in IBD ileum in 220 
comparison to control ileum. No significant difference was found between pouch and both IBD 221 
and control ileum (after Bonferroni correction). SERT transcript levels did not significantly differ 222 
among all the aforementioned groups (Figure 3B). 223 
 224 
Ex vivo effect of infliximab on TpH-1 and SERT transcripts and on IL-6 and IL-8 225 
production. In order to investigate the effect of infliximab on serotonin, we measured TpH-1 and 226 
SERT expression in the pouch biopsies obtained from five patients undergoing restorative 227 
proctocolectomy,  and cultured ex vivo with infliximab or its isotype control (IgG1) (Figure 4A). 228 
Both TpH-1 and SERT transcript levels did not significantly differ between the biopsies cultured 229 
with infliximab in comparison to those cultured with IgG1. 230 
 231 
In order to investigate the effect of infliximab on innate cytokine production, we measured IL-6 232 
and IL-8 levels in the supernatant of mucosal pouch biopsy samples obtained from five patients 233 
undergoing restorative proctocolectomy and cultured ex vivo with infliximab or IgG1 (Figure 4B). 234 
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IL-6 levels did not significantly differ in the supernatants of biopsies cultured with infliximab 235 
(mean 1497 ± 1133 pg/mL) in comparison to those cultured with IgG1 (mean 634 ± 802 pg/mL). 236 
Likewise, IL-8 levels did not significantly differ in the supernatants of biopsies cultured with 237 
infliximab (mean 64458 ± 25989 pg/mL) in comparison to those with IgG1 (mean 33858 ± 14193 238 
pg/mL). 239 
 240 
Discussion 241 
 242 
Herein this exploratory study, we show an increase in neuroendocrine cells in pouch mucosa. 243 
Several studies have reported changes in neuroendocrine cell number in IBD mucosa, including 244 
patients with pouch (Table 1).3-11,18-20 Nevertheless, the current knowledge on this topic is 245 
conflicting due to the use of different counting methods (Table 1) and hormones tested. A high 246 
number of neuroendocrine cells has been observed not only in IBD mucosa,5 but also in 247 
lymphocytic colitis,24-26 and in the duodenum of patients with celiac disease.12 By enumerating 248 
neuroendocrine cells through an accurate method which we already validated in the small bowel 249 
mucosa -i.e. counting per 100 crypt cells in well-oriented biopsy specimens-,12 we showed an 250 
increase in the number of CgA-positive cells in pouch mucosa and IBD ileum. Our data showing 251 
a higher number of cells positive for the pan-neuroendocrine marker chromogranin A (CgA) in 252 
the ileum of CD patients are in agreement with previous studies.3,4 Moreover, there is growing 253 
evidence of the pro-inflammatory role of serotonin in gastrointestinal disorders; in particular, 254 
serotonin triggers the release of pro-inflammatory cytokines from macrophages.27,28 EC cell 255 
hyperplasia has been also observed in lymphocytic colitis,26 and in a specific population with 256 
irritable pouch syndrome.20 According to all these findings, in our series of patients with a pouch 257 
and in IBD ileum, serotonin-positive cells were significantly increased compared to controls. 258 
Notably, we here describe for the first time an increase of serotonin-positive cells in the inflamed 259 
ileum of UC patients and further studies are needed in order to assess a possible independent 260 
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role of these cells in UC-associated ileitis.29 All the studies on serotonin-positive cells in UC 261 
patients have been conducted in colonic or rectal mucosa and reported controversial data.5,8-11 262 
Finally, the presence of dysplasia or cancer leading to proctocolectomy did not influence neither 263 
CgA-positive cells nor serotonin-producing cells in pouch mucosa. 264 
 265 
As EC cells might be underestimated by immunohistochemistry and may not reflect the increase 266 
of serotonin production, we measured serotonin rate-limiting enzyme TpH-1 in the pouch 267 
biopsies by quantitative RT-PCR. Besides TpH-2 that is only expressed in human brain, TpH-1 268 
is the only enzyme that synthetizes serotonin, therefore could be considered a reliable indirect 269 
measure of serotonin production.29 Our results showing higher TpH-1 transcript levels in IBD 270 
ileum compared to controls are in keeping with the known pro-inflammatory effects of this 271 
molecule and the EC cell hyperplasia identified in this group. TpH-1 transcript levels in patients 272 
with pouch are increased compared to controls, but to a level that is just below statistical 273 
significance. Moreover, there is a weak negative correlation between the percentage of CgA-274 
positive cells or that of serotonin-positive cells and the degree of acute plus chronic 275 
inflammation. Therefore, it is reasonable to assume that the small number of patients with a high 276 
degree of pouch inflammation may justify these findings, as well as other possible mechanisms 277 
of inflammation we have not looked at in the present study (i.e., dysbiosis, mucosal ischemia, 278 
genetic susceptibility, immune dysregulation).31 Peripheral TpH-1 inhibitors have been 279 
successfully tested in murine models of IBD.32 As serotonin is rapidly removed from the 280 
interstitial space by enterocytes through SERT, we also detected the mucosal transcripts of this 281 
transporter, reported to be reduced in the rectum of UC patients.11 However, we did not find any 282 
change in the mucosal transcript level of SERT in patients with pouch in comparison to control 283 
subjects. We then measured TpH-1 and SERT expression in the pouch biopsies cultured ex vivo 284 
with infliximab, an anti-TNF-α monoclonal antibody that has been demonstrated to exert a 285 
therapeutic effect on patients with pouchitis.33 Nonetheless, infliximab did not modify TpH-1 and 286 
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SERT levels. In order to validate our ex vivo experiments, in the biopsy culture supernatants we 287 
detected IL-6, a cytokine of the innate immunity, and IL-8, a chemokine, known to be increased 288 
in pouch mucosa.34,35 Infliximab was able to reduce both IL-6 and IL-8, although not significantly. 289 
A likely explanation for this finding is the lack of statistical power, with the subsequent high risk 290 
of β-error, given that most of the enrolled patients with a pouch only had mild mucosal 291 
inflammation. As already mentioned, serotonin causes the release of these cytokines from 292 
macrophages28 and this may explain the modest efficacy of infliximab that blocks a different 293 
pathway of inflammation. Several 5-HT3 receptor antagonists have been reported to ameliorate 294 
intestinal inflammation, but none of them has been approved so far.36 We therefore envisage 295 
that future studies will provide new insights to this regard. Finally, in contrast with Schaeffer et 296 
al.,37 none of our pouch biopsies was associated with increased IELs infiltration, and no 297 
correlation between IELs count and CgA- or serotonin-positive cells was observed in our pouch 298 
biopsies.  299 
 300 
In conclusion, neuroendocrine cells are increased in the mucosa of patients with pouch, although 301 
no clear correlation was seen with the degree of inflammation, nor with the presence of previous 302 
dysplasia. We cannot exclude that the different immunological and microbial luminal milieu in 303 
which the “orthotopically-transplanted ileum” is transposed when the pouch is crated might have 304 
an influence on the neuroendocrine cell compartment. The significance of this finding is yet to 305 
be fully understood, but could represent a future target of intervention. Larger studies are needed 306 
to clarify whether the lack of change of TpH-1 and SERT transcript levels may be attributed to a 307 
small sample size or to other unexplored causes.  308 
Guarantor of the article: Antonio Di Sabatino 309 
 310 
Statement of author contributions: All authors participated in drafting of the manuscript or 311 
critical revision of the manuscript for important intellectual content, and provided approval of the 312 
 13 
 
final submitted version. Individual contributions are as follows. ADS: study concept and design, 313 
analysis and interpretation of data, statistical analysis, manuscript preparation, principal 314 
investigator, and guarantor. PG: acquisition of data, technical and material support, statistical 315 
analysis, manuscript preparation. AV, EB, CK, GB, MM, MVL, NA, MC, RM, PF, MT and FC: 316 
acquisition of data, technical and material support. GS and SA: clinical management of patients. 317 
ADS and OL: fund raising. GRC: study supervision, fund raising. 318 
 319 
Personal acknowledgments: None 320 
 14 
 
References 321 
 322 
1. El-Salhy M, Hatlebakk JG, Gilja OH. Abnormalities in endocrine and immune cells are 323 
correlated in dextran-sulfate-sodium-induced colitis in rats. Mol Med Rep 2017;15:12-20.  324 
2. El-Salhy M, Mazzawi T, Umezawa K, et al. Enteroendocrine cells, stem cells and 325 
differentiation progenitors in rats with TNBS-induced colitis. Int J Mol Med 2016;38:1743-51. 326 
3. Bishop AE, Pietroletti R, Taat CW, et al. Increased populations of endocrine cells in Crohn's 327 
ileitis. Virchows Arch A Pathol Anat Histopathol 1987;410:391-6. 328 
4. Moran GW, Pennock J, McLaughlin JT. Enteroendocrine cells in terminal ileal Crohn's 329 
disease. J Crohns Colitis 2012;6:871-80. 330 
5. El-Salhy M, Danielsson A, Stenling R, et al. Colonic endocrine cells in inflammatory bowel 331 
disease. J Intern Med 1997;242:413-9. 332 
6. Gledhill A, Enticott ME, Howe S. Variation in the argyrophil cell population of the rectum in 333 
ulcerative colitis and adenocarcinoma. J Pathol 1986;149:287-91. 334 
7. Watanabe T, Kubota Y, Sawada T, et al. Distribution and quantification of somatostatin in 335 
inflammatory disease. Dis Colon Rectum 1992;35:488-94. 336 
8. Ahonen A, Kyösola K, Penttilä O. Enterochromaffin cells in macrophages in ulcerative colitis 337 
and irritable colon. Ann Clin Res 1976;8:1-7. 338 
9. Kyösola K, Penttilä O, Salaspuro M. Rectal mucosal adrenergic innervation and 339 
enterochromaffin cells in ulcerative colitis and irritable colon. Scand J Gastroenterol 340 
1977;12:363-7. 341 
10. Verity MA, Mellinkoff SM, Frankland M, et al. Serotonin content and argentaffin and Paneth 342 
 15 
 
cell changes in ulcerative colitis. Gastroenterology 1962;43:24-31. 343 
11. Coates MD, Mahoney CR, Linden DR, et al. Molecular defects in mucosal serotonin content 344 
and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel 345 
syndrome. Gastroenterology 2004;126:1657-64. 346 
12. Di Sabatino A, Giuffrida P, Vanoli A, et al. Increase in neuroendocrine cells in the duodenal 347 
mucosa of patients with refractory celiac disease. Am J Gastroenterol 2014;109:258-69. 348 
13. Rindi G, Leiter AB, Kopin AS, et al. The "normal" endocrine cell of the gut: changing concepts 349 
and new evidences. Ann N Y Acad Sci 2004;1014:1-12. 350 
14. Stefuli J, Cicin-Sain L, Schauenstein K, Jernej B. Serotonin and immune response effect of 351 
the amine on in vitro proliferation of rat lymphocytes. Neuroimmunomodulation 2001;9:103-352 
9. 353 
15. Li N, Ghia JE, Wang H, et al. Serotonin activates dendritic cell function in the context of gut 354 
inflammation. Am J Pathol 2011;178:662-71. 355 
16. Laberge S, Cruikshank WW, Beer DJ, et al. Secretion of IL-16 (lymphocyte chemoattractant 356 
factor) from serotonin-stimulated CD8+ T cells in vitro. J Immunol 1996;156:310-5. 357 
17. Ghia JE, Li N, Wang H, et al. Serotonin has a key role in the pathogenesis of experimental 358 
colitis. Gastroenterology 2009;137:1649-60. 359 
18. Greenberg GR, Buchan AM, McLeod RS, et al. Gut hormone responses after reconstructive 360 
surgery for ulcerative colitis. Gut 1989;30:1721-30. 361 
19. Pietroletti R, Slors JF, Carlei F, et al. Immunocytochemical study of endocrine cells in pelvic 362 
ileal reservoirs. Dis Colon Rectum 1990;33:703-6. 363 
20. Shen B, Liu W, Remzi FH, et al. Enterochromaffin cell hyperplasia in irritable pouch 364 
 16 
 
syndrome. Am J Gastroenterol 2008;103:2293-300. 365 
21. Shen B, Achkar JP, Lashner BA, et al. Endoscopic and histologic evaluation together with 366 
symptom assessment are required to diagnose pouchitis. Gastroenterology 2001;121:261-367 
267. 368 
22. Moskowitz RL, Shepherd NA, Nicholls RJ. An assessment of inflammation in the reservoir 369 
after restorative proctocolectomy with ileoanal ileal reservoir. Int J Colorectal Dis 1986;1:167-370 
74. 371 
23. Naini BV, Cortina G. A histopathologic scoring system as a tool for standardized reporting of 372 
chronic (ileo)colitis and independent risk assessment for inflammatory bowel disease. Hum 373 
Pathol 2012;43:2187-96. 374 
24. El-Salhy M, Lomholt-Beck B, Gundersen TD. High chromogranin A cell density in the colon 375 
of patients with lymphocytic colitis. Mol Med Rep 2011;4:603-5. 376 
25. El-Salhy M, Gundersen D, Hatlebakk JG, et al. Chromogranin A cell density as a diagnostic 377 
marker for lymphocytic colitis. Dig Dis Sci 2012;57:3154-9. 378 
26. El-Salhy M, Gundersen D, Hatlebakk JG, et al. High densities of serotonin and peptide YY 379 
cells in the colon of patients with lymphocytic colitis. World J Gastroenterol 2012;18:6070-5. 380 
27. Khan WI, Ghia JE. Gut hormones: emerging role in immune activation and inflammation. Clin 381 
Exp Immunol 2010;161:19-27. 382 
28. Ghia JE, Li N, Wang H, et al. Serotonin has a key role in pathogenesis of experimental colitis. 383 
Gastroenterology 2009;137:1649-60.  384 
29. Patil DT, Odze RD. Backwash is hogwash: the clinical significance of ileitis in ulcerative 385 
colitis. Am J Gastroenterol 2017;112:1211-4. 386 
 17 
 
30. Walther DJ, Peter JU, Bashammakh S, et al. Synthesis of serotonin by a second tryptophan 387 
hydroxylase isoform. Science. 2003;299:76.  388 
31. Schieffer KM, Williams ED, Yochum GS, et al. Review article: the pathogenesis of pouchitis. 389 
Aliment Pharmacol Ther 2016;44:817-35. 390 
32. Margolis KG, Stevanovic K, Li Z, et al. Pharmacological reduction of mucosal but not 391 
neuronal serotonin opposes inflammation in mouse intestine. Gut 2014;63:928-37. 392 
33. Kelly OB, Rosenberg M, Tyler AD, et al. Infliximab to treat refractory inflammation after pelvic 393 
pouch surgery for ulcerative colitis. J Crohns Colitis 2016;10:410-7. 394 
34. Gionchetti P, Campieri M, Belluzzi A, et al. Mucosal concentrations of interleukin-1 beta, 395 
interleukin-6, interleukin-8, and tumor necrosis factor-alpha in pelvic ileal pouches. Dig Dis 396 
Sci 1994;39:1525-31. 397 
35. Patel RT, Bain I, Youngs D, et al. Cytokine production in pouchitis is similar to that in 398 
ulcerative colitis. Dis Colon Rectum 1995;38:831-7. 399 
36. Kato S. Role of serotonin 5-HT₃ receptors in intestinal inflammation. Biol Pharm Bull 400 
2013;36:1406-9. 401 
37. Schaeffer DF, Walsh JC, Tyler AD, et al. Intraepithelial lymphocytosis is a frequent finding in 402 
biopsies from ileal pouch-anal anastomoses. Hum Pathol 2016;54:31-6. 403 
 18 
 
Figure legend 404 
 405 
Figure 1. A-H. Immunohistochemical detection of chromogranin A (CgA) and serotonin. 406 
The immunohistochemical detection of CgA showed numerous CgA-positive cells in the pouch 407 
mucosa of a patient undergoing restorative proctocolectomy and ileal pouch-anal anastomosis 408 
for ulcerative colitis (A) and in the ileal crypt epithelium of a patient with active ulcerative colitis 409 
(B) and Crohn’s disease (C). On the contrary, CgA positivity was limited to a few cells in the ileal 410 
crypt epithelium of a control subject (D). Serotonin immunostaining revealed numerous positive 411 
cells in the pouch mucosa of the patient shown in A (E), in the ileal mucosa of the patients with 412 
ulcerative colitis shown in B (F) and Crohn’s disease shown in C (G), compared with serotonin-413 
positive cells in the ileal crypt epithelium of the control subject shown in D (H). Data are 414 
representative of staining performed in the pouch of 17 patients undergoing restorative 415 
proctocolectomy, and in the ileum of 17 patients with active inflammatory bowel disease and 16 416 
control subjects.  417 
 418 
Figure 2. A-B. Number of chromogranin A (CgA)-positive cells and serotonin-positive cells 419 
counted per 100 crypt cells, and their correlation. Number of CgA-positive cells (A) and 420 
serotonin-positive cells (B), both counted per 100 crypt cells, in the pouch mucosa of 17 patients 421 
undergoing restorative proctocolectomy and ileal pouch-anal anastomosis for ulcerative colitis, 422 
and in the ileal crypt epithelium of 17 patients with active inflammatory bowel disease (IBD) and 423 
16 control subjects. Horizontal bars represent mean values. (C) Significant positive correlation 424 
between the number of chromogranin A (CgA)-positive cells per 100 crypt cells and the number 425 
of serotonin-positive cells per 100 crypt cells.  426 
 427 
Figure 3. A-B. Tryptophan hydroxylase (TpH)-1 and serotonin-selective reuptake 428 
 19 
 
transporter (SERT) transcripts. (A) TpH-1 and (B) SERT transcripts, measured by quantitative 429 
RT-PCR, in the pouch mucosa of six patients undergoing restorative proctocolectomy and ileal 430 
pouch-anal anastomosis for ulcerative colitis, and in the ileal mucosa of six patients with active 431 
inflammatory bowel disease (IBD), and seven control subjects. The values, normalized for 432 
GAPDH and representing the fold change in transcript expression compared to control subjects, 433 
are reported as means. 434 
 435 
Figure 4. A-B. Effect of infliximab on the pouch mucosa grown ex vivo. (A) Tryptophan 436 
hydroxylase (TpH)-1 and serotonin-selective reuptake transporter (SERT) transcripts, measured 437 
by quantitative RT-PCR, in organ culture pouch biopsies collected from five patients undergoing 438 
restorative proctocolectomy and ileal pouch-anal anastomosis for ulcerative colitis and cultured 439 
for 24h with IgG1 or infliximab. The values, normalized for GAPDH and representing the fold 440 
change in transcript expression compared to IgG1, are reported as means. (B) Interleukin (IL)-441 
6 and IL-8 concentrations were detected by ELISA in the supernatants of the same organ culture 442 
biopsies used for quantitative RT-PCR for TpH-1 and SERT. Results are reported as means. 443 
444 
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Table 1. Studies analyzing neuroendocrine cells in inflammatory bowel disease 
 
 
Authors 
 
Disease 
type 
 
N 
 
Site 
 
 
Detection method 
 
Counting method 
 
Findings 
 
Greenberg et al.18  
 
 
Pietroletti et al.19  
 
Pouchitis 
 
 
Pouchitis 
 
12 
 
 
9 
 
Pouch 
 
 
Pouch 
 
IHC for neurotensin, enteroglucagon and 
PYY 
 
IHC for CgA, enteroglucagon, serotonin, 
PYY, neurotensin and somatostatin 
 
Per mm of epithelium 
 
 
Per visual field (x10)  
 
Decrease in neurotensin-, enteroglucagon- and PYY-positive cells 
in pouch mucosa (compared to normal ileal mucosa) 
 
Decrease in neurotensin-, enteroglucagon-, PYY-positive cells in 
pouch mucosa (compared to normal ileal mucosa). No difference 
of CgA- and somatostatin-positive 
 
Shen B et al.20  
 
 
Verity et al.10  
 
 
Watanabe et al.7  
 
 
El-Salhy et al.5  
 
 
 
Ahonen et al.8  
 
 
Kyösola et al.9  
 
 
Gledhill et al.6  
 
 
 
Coates et al.11  
 
 
Bishop et al.3  
 
 
Moran et al.4  
 
IPS 
 
 
UC 
 
 
UC 
 
 
UC 
 
 
 
UC 
 
 
UC 
 
 
UC 
 
 
 
UC 
 
 
CD 
 
 
CD 
 
36 
 
 
8 
 
 
25 
 
 
17 
 
 
 
6 
 
 
13 
 
 
10 
 
 
 
22 
 
 
10 
 
 
38 
 
 
Pouch 
 
 
Colon 
 
 
Colon 
 
 
Colon 
 
 
 
Rectum 
 
 
Rectum 
 
 
Rectum 
 
 
 
Rectum 
 
 
Ileum 
 
 
Ileum 
 
IHC for serotonin 
 
 
Gomori silver technique and diazo method 
 
 
IHC for somatostatin 
 
 
IHC for CgA, enteroglucagon, serotonin, PYY 
and PP 
 
 
Formaldehyde-induced fluorescence after  
freeze-drying and Epon embedding 
 
Glyoxylic-acid-induced fluorescence 
histochemical method 
 
Grimelius’s silver impregnation 
 
 
 
IHC for CgA and serotonin 
 
 
IHC for CgA, glucagon (N-terminal), 
somatostatin, neurotensin and PYY 
 
IHC for CgA and PYY; 
immunofluorescence for GLP-1 
 
 
Per 4200 epithelial 
cells 
 
Per 100 crypts 
 
 
Per 1000 epithelial 
cells 
 
Area of positive 
cells/area of epithelial 
cells 
 
Per crypt 
 
 
On a scale from 0 to 
10  
 
Per crypt or mm of 
epithelium or mm of 
muscularis mucosae 
 
Per mm of muscularis 
mucosae 
 
Per mm of muscularis 
mucosae 
 
Per villous-crypt 
unit/HPF 
 
 
Increase in serotonin-positive cells in IPS (compared to normal 
pouch mucosa) 
 
Decrease in serotonin-positive cells in UC (compared to normal 
colonic mucosa) 
 
Decrease in somatostatin-positive cells in CD (compared to 
normal colonic mucosa) 
 
Increase in CgA- and serotonin-positive cells in UC (compared to 
normal colonic mucosa) 
 
 
Decrease in serotonin-positive cells in UC (compared to normal 
rectal mucosa) 
 
Decrease in serotonin-positive cells in UC (compared to normal 
rectal mucosa) 
 
Increase in neuroendocrine cells in UC (compared to normal 
rectal mucosa) 
 
 
Decrease in serotonin-positive cells in UC (compared to normal 
rectal mucosa) 
 
Increase in CgA-positive and serotonin-positive cells (compared to 
normal ileal mucosa) 
 
Increase in CgA-positive and GLP-1-positive cells, but not in PYY-
positive cells (compared to normal ileal mucosa) 
 
 
CD, Crohn’s disease; CgA, chromogranin; GLP, glucagon-like peptide; HPF, high power field; IHC, immunohistochemistry; IPS, irritable pouch syndrome; PP, pancreatic polypeptide; PYY, peptide YY; UC, ulcerative 
colitis. 
Table 2. Clinical, endoscopic and pathological features of 17 patients undergoing restorative proctocolectomy and ileal pouch-anal anastomosis for 
ulcerative colitis 
 
 
Pt 
 
Sex 
 
Age 
(yr) 
 
Age at UC 
diagnosis  
(yr) 
 
Age at 
proctocolectomy  
(yr) 
 
Smoking 
habit 
 
 
Reasons leading to 
proctocolectomy 
 
Endoscopic  
Inflammation 
according to 
PDAI 
 
Moskowitz criteria 
 
IELs 
(%) 
 
Acute 
(0-6)                 
 
Chronic 
(0-6)                 
 
Total 
(0-12) 
 
 
1 F 44 34 39 
 
Smoker Unresponsive to medical treatment 
 
0 
 
1 2 
 
3 
 
6.5 
2 F 46 25 41 Never smoker Unresponsive to medical treatment 0 1 5 6 5.4 
3 M 56 33 52 Past smoker Dysplasia  2 3 4 7 6.0 
4 M 28 15 23 Past smoker Toxic megacolon 1 1 5 6 3.4 
5 M 57 45 53 Never smoker Unresponsive to medical treatment 2 3 6 9 5.2 
6 F 61 28 58 Smoker Dysplasia 2 3 5 8 10.2 
7 F 26 17 22 Never smoker Unresponsive to medical treatment 3 4 6 10 4.0 
8 F 40 32 37 Never smoker Unresponsive to medical treatment 2 1 5 6 4.0 
9 F 40 22 35 Never smoker Unresponsive to medical treatment 2 1 2 3 5.8 
10 M 43 10 37 Past smoker Dysplasia  1 1 5 6 3.0 
11 M 42 38 40 Past smoker Unresponsive to medical treatment 0 1 4 5 5.2 
12 M 64 61 62 Never smoker Unresponsive to medical treatment 2 1 5 6 4.6 
13 M 28 26 32 Past smoker Toxic megacolon  1 1 4 5 9.8 
14 F 63 40 58 Past smoker Cancer (T1N0) 3 3 5 8 2.2 
15 F 45 28 39 Smoker Unresponsive to medical treatment 2 1 5 6 5.6 
16 M 37 26 32 Past smoker Unresponsive to medical treatment 3 3 2 5 6.6 
17 M 64 59 60 Never smoker Unresponsive to medical treatment 3 6 6 12 11.4 
 
  F, female; IEL, intraepithelial lymphocyte; M, male; PDAI, Pouchitis Disease Activity Index; Pt, patient; UC, ulcerative colitis; yr, years. 
